| Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. | |
| | |
MedLine Citation:
|
PMID: 22000938 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Data on attaining and maintaining symptom remission associated with specific antipsychotic medications are rare and variant. AIMS: To examine remission rates and their variation by antipsychotic medication in chronic schizophrenia in the National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) given it has an 18-month duration and representative antipsychotic medications. METHODS: Symptom remission was examined using the Remission in Schizophrenia Working Group remission criteria of attaining and maintaining for 6months with mild ratings on 8 specific Positive and Negative Syndrome Scale (PANSS) items. Remission rates were assessed (a) up to 18months across CATIE's switching phases (n=1332); and (b) in phase 1 (that involved double-blind randomization to one of five antipsychotic medications) to compare antipsychotic medication differences in attaining and maintaining remission among patients not in remission at baseline (n=941). RESULTS: At baseline 16.2% of patients were in symptomatic remission. Across the medication phases of CATIE only 11.7% attained and then maintained at least 6months of symptomatic remission, and 55.5% (n=623) experienced no symptom remission at any visit. During the first medication randomization phase, attaining and maintaining remission for 6months was highest for the olanzapine (12.4%) medication group followed by the quetiapine (8.2%), perphenazine (6.8%), ziprasidone (6.5%), and risperidone (6.3%) groups. CONCLUSIONS: As currently defined, remission appears to be a very difficult therapeutic target to attain and maintain in chronic schizophrenia and may differ by antipsychotic medication. Pragmatically, remission gradients may be effectively studied by applying modified duration and symptom criteria. |
| | |
Authors:
|
Stephen Z Levine; Jonathan Rabinowitz; Haya Ascher-Svanum; Douglas E Faries; Anthony H Lawson |
Related Documents
:
|
21747988 - Strategies in the surgical management of atrial fibrillation. 290278 - Use of an incisor diagnostic triangle for evaluating incisor positions relative to the ... 20463908 - Alternative approach to treating malignant glaucoma after trabeculectomy with unplanned... 18537988 - Recurrent serous macular detachment after topical ocular hypotensive medication. 15943958 - Medication quantification scale version iii: update in medication classes and revised d... 11054508 - Does gender bias exist in the medical management of heart failure? |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-10-13 |
Journal Detail:
|
Title: Schizophrenia research Volume: - ISSN: 1573-2509 ISO Abbreviation: - Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8804207 Medline TA: Schizophr Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier B.V. All rights reserved. |
Affiliation:
|
Bar Ilan University, Ramat Gan, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Test-retest reliability of Attention Network Test measures in schizophrenia.
Next Document: Advanced paternal and grandpaternal age and schizophrenia: A three-generation perspective.